Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials

Li, Chengyu; Wang, Ping; Zhang, Li; Li, Min; Xiang, Lei; Liu, Si; Feng, Zhiqiao; Yao, Yong‐Ming; Chang, Bai; Liu, Baoshan; Shang, Hongcai

doi:10.1016/j.jep.2018.05.043

Cited by 62 publications

(65 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…XBJ has been approved for the treatment of severe infection (sepsis). For a long period of time in China, it was believed that XBJ could improve prognosis in severe lung infection [33] as well as 28-day mortality rate, Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score, white blood cell (WBC) count, and temperature in sepsis patients without causing serious adverse events. A prospective, randomized controlled trial in 33 hospitals in China, published in September 2019, showed that XBJ can signi cantly improve the primary endpoint of pneumonia severity in patients with severe communityacquired pneumonia, as well as secondary endpoints such as mortality rate, mechanical-ventilation duration, and length of intensive-care unit (ICU) stay [34].…”

Section: Discussionmentioning

confidence: 99%

Examining the effector mechanisms of Xuebijing Injection on COVID-19 based on network pharmacology.

Zheng

Yan

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: To examine the potential effector mechanisms of Xuebijing (XBJ) on coronavirus disease 2019 (COVID-19) based on network pharmacology.Methods: We searched Chinese and international papers to obtain the active ingredients of XBJ. Then, we compiled COVID-19 disease targets from the GeneCards gene database and via literature searches. Next, we used the SwissTargetPrediction database to predict XBJ’s effector targets and map them to the abovementioned COVID-19 disease targets in order to obtain potential therapeutic targets of XBJ. Cytoscape software version 3.7.0 was used to construct a “XBJ active-compound-potential-effector target” network and protein-protein interaction (PPI) network, and then to carry out network topology analysis of potential targets. We used the ClueGO and CluePedia plugins in Cytoscape to conduct gene ontology (GO) biological process (BP) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis of XBJ’s effector targets. Results: We obtained 144 potential COVID-19 effector targets of XBJ. Fourteen of these targets—glyceraldehyde 3-phosphate dehydrogenase (GAPDH), albumin (ALB), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), Caspase-3 (CASP3), signal transducer and activator of transcription 3 (STAT3), MAPK8, prostaglandin-endoperoxide synthase 2 (PTGS2), JUN, interleukin-2 (IL-2), estrogen receptor 1 (ESR1), and MAPK14—had degree values >40 and therefore could be considered key targets. They participated in extracellular signal–regulated kinase 1 and 2 (ERK1, ERK2) cascade, the T-cell receptor signaling pathway, activation of MAPK activity, cellular response to lipopolysaccharide, and other inflammation- and immune-related BPs. XBJ exerted its therapeutic effects through the renin–angiotensin system (RAS), nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), MAPK, phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)–protein kinase B (Akt)–vascular endothelial growth factor (VEGF), toll-like receptor (TLR), TNF, and inflammatory-mediator regulation of transient receptor potential (TRP) signaling pathways to ultimately construct a “ingredient-target-pathway” effector network. Conclusion: The active ingredients of XBJ regulated different genes, acted on different pathways, and synergistically produced anti-inflammatory and immune-regulatory effects, which fully demonstrated the synergistic effects of different components on multiple targets and pathways. Our study demonstrated that existing studies on the pharmacological mechanisms of XBJ in the treatment of sepsis and severe pneumonia, could explain the effector mechanism of XBJ in COVID-19 treatment, and those provided a preliminary examination of the potential effector mechanism in this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Examining the effector mechanisms of Xuebijing Injection on COVID-19 based on network pharmacology.

Zheng

Yan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…e balance between Treg cells and 17 cells has been considered an important cause of RA development [9]. Additionally, 1 cells are mainly characterized by IFN-c secretion and can mediate cellular immunity, whereas 2 cells mainly secrete IL-4 and mediate humoral immunity [10]. An imbalanced 1/ 2 cell ratio also contributes to RA development, while reduction of the 1/ 2 ratio has therapeutic effects on RA [11,12].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Effect of Xuebijing, a Traditional Chinese Medicine Injection, on Rheumatoid Arthritis

Wang

Sun

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Traditional Chinese medicine considers that rheumatoid arthritis (RA) is caused by blood stasis, heat, and toxins. Xuebijing (XBJ), a traditional Chinese medicine compound injection, activates blood circulation to dissipate blood stasis, eliminating pathogenic heat from the blood and degrading toxins. XBJ was approved by the China FDA to treat for many years. This study examined the potential therapeutic effects of XBJ on RA and rat collagen-induced arthritis (CIA). Methods. XBJ was cultured with the synovial fluid (SF) of RA patients. XBJ was also injected into CIA rats. Changes in Treg and Th17 cell levels in the peripheral blood (PB), SF, and spleen and changes in Th1/Th2 and cytokine levels in PB were detected using flow cytometry. Four RA patients were treated using XBJ based on Chinese medical theory and Chinese medicine indications. Results. Following culture with XBJ, the proportion of Treg cells (P=0.007) was significantly increased in RA SF, while the Th1/Th2 ratio remained unchanged. After XBJ treatment, CIA in rats was significantly relieved (P<0.001). The Treg cell proportion was significantly increased in the PB, SF, and spleen in the treated rats, while the number of Th17 cells decreased. The ratio of Th1/Th2 remained unchanged in PB, and the levels of IL-1β, IL-6, IL-17A, IFN-γ, and TNF-α decreased (P=0.031, P<0.001, P<0.001, P<0.001, and P=0.001, respectively). After XBJ treatment, the disease activity score-28 (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, Th17 cell number, and Th1/Th2 cell ratio in the four RA patients were significantly decreased, while the Treg cell proportion was increased. Conclusion. XBJ can restore the immune balance to treat RA and CIA. Therefore, XBJ could be a potential therapeutic drug for RA.

show abstract

“…Recently, particular concerns have been raised on the quality control of traditional Chinese medicines (TCMs) because of their complex ingredients and unclear active substances. It is important to quantitatively characterize the multiple components in TCMs (Li et al, , ; Xiong et al, ; Yuan, Chen, Zhou, Lin, & Zhang, ). So far, 71 compounds have been identified in HQJZ based on UHPLC‐Q Exactive‐MS, including 20 compounds from Astragali Radix, 14 compounds from Paeoniae Radix Alba, 37 compounds from Glycyrrhizae Radix et Rhizoma Praeparata cum Melle, three compounds from Rhizoma Zingiberis Recens, and two compounds from Cinnamomi Ramulus and Jujubae Fructus, respectively (Hu, Xu, Qin, & Liu, ).…”

Section: Introductionmentioning

confidence: 99%

Rapid quantitative analysis of 18 chemical constituents in HuangQi JianZhong Tang based on UHPLC–MS

Jia

Qin

2020

Biomedical Chromatography

View full text Add to dashboard Cite

A rapid, highly sensitive, and specific analytical method using ultra‐high‐performance liquid chromatography‐triple quadruple MS was developed to quantitatively measure 18 chemical constituents in Huangqi Jianzhong Tang (HQJZ), a famous traditional Chinese medicine formula. Chromatographic separation was performed on a Waters ACQUITY UPLC HSS T3 column (2.1 mm × 100 mm, 1.8 μm) with a gradient mobile phase (A: 0.1% aqueous formic acid and B: acetonitrile) at a flow rate of 0.25 mL/min. The chromatographic peaks of 18 components were identified by comparing with the reference compounds. Multiple reaction monitoring was employed for quantitative analysis of the components. Seven batches of HQJZ samples were analyzed with a good linear regression relationship (R2, .9978–.9993), precisions [relative standard deviation (RSD), 0.90%–3.60%], repeatability (RSD, 2.50%–4.00%), stability (RSD, 1.00%–4.00%), and recovery (96.10%–104.30%). Based on this established method, the present study offered a highly sensitive, specific, and rapid determination method for identification of 18 compounds, which greatly promoted the systemic quality control of HQJZ.

show abstract

Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials

Cited by 62 publications

References 18 publications

Examining the effector mechanisms of Xuebijing Injection on COVID-19 based on network pharmacology.

Examining the effector mechanisms of Xuebijing Injection on COVID-19 based on network pharmacology.

Therapeutic Effect of Xuebijing, a Traditional Chinese Medicine Injection, on Rheumatoid Arthritis

Rapid quantitative analysis of 18 chemical constituents in HuangQi JianZhong Tang based on UHPLC–MS

Contact Info

Product

Resources

About